90-Second Read: Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of Hantavirus, bunyavirus and... These antiviral molecules target a highly conserved region of the viral replication enzyme, specifically the L-protein of Andes Hantavirus, which is essential for viral replication and transcription. About Cocrystal Pharma's Structure-Based Drug Discovery Platform Cocrystal is leveraging its structure‑based drug discovery platform technology to design next‑generation antiviral candidates that precisely target viral replication mechanisms. BOTHELL, Wash., May 26, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.

Hantaviruses are primarily transmitted by rodents, although human-to-human transmission can occur through prolonged close contact. Andes Hantavirus, a member of the genus Hantavirus, is endemic in Argentina and Chile and causes Hantavirus cardiopulmonary syndrome (HCPS), which is associated with a case fatality rate of up to 50%. Currently, there are no approved antivirals or vaccines for Andes Hantavirus or other Hantaviruses. This approach streamlines candidate identification and optimization, enabling more rapid progression of promising therapies with robust resistance and safety profiles.

By binding to highly conserved regions of viral enzymes, the Company's compounds aim to maintain potency against mutating strains while minimizing off‑target effects, offering potentially safer, broad‑spectrum antiviral solutions. The goal of this technology is to facilitate the development of novel broad-spectrum antivirals for the treatment of acute, chronic and potentially pandemic viral diseases. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create viable antiviral drugs. Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment...

We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatmentFully enrolled first cohort is assessing... Some or all of the events anticipated by these forward-looking statements may not occur.